ArticleCureus2023
Association Between Subclinical Hypothyroidism and the Prognosis of Diabetes Mellitus and Subsequent Complications: A Retrospective Cohort Study.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammatory Profile Assessment in a Highly Selected Athyreotic Population Undergoing Controlled and Standardized Hypothyroidism.Biomedicines · 2024Article
- Characteristics of blood lipid and metabolic indicators in subclinical hypothyroidism patients: a retrospective study.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Diabetes mellitus (DM) and subclinical hypothyroidism (SCH) are prevalent metabolic and endocrine disorders. Previous studies have suggested potential associations between SCH and metabolic disorders, including DM. This study aimed to explore the relationship between SCH and DM in patients from the Qassim Region in Saudi Arabia. Methods A retrospective cohort study was conducted on patients who attended the Qassim University clinics from December 2017 to December 2021. Participants were divided into two groups: SCH patients without a history of DM and age- and sex-matched controls without SCH or DM. Parameters, such as DM occurrence, DM duration, glycosylated hemoglobin (HbA1c) values, and metformin use, were evaluated. Results The prevalence of DM was 70.4% in the SCH group and 83.3% in the non-SCH group, with no significant difference between the groups (p=0.203). The mean HbA1c values and DM duration showed no significant variations between the two groups. However, metformin use was significantly higher in the SCH group at 74.1% compared to 50.0% in the non-SCH group (p=0.047). No correlation was observed between HbA1c and thyroid-stimulating hormone (TSH) levels. Conclusions While the study indicates a potential association between SCH and DM management, especially with regard to metformin usage, there does not appear to be a significant relationship between SCH and DM development or progression in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.